Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8780796 | Gynecologic Oncology | 2017 | 8 Pages |
Abstract
The vast majority of SCCOHT demonstrate genomic SMARCA4 loss with only rare co-occurring alterations. Our data support a role for CGP in the diagnosis and management of SCCOHT and of other lesions with overlapping histological and clinical features, since identifying the former by genomic profile suggests benefit from an appropriate regimen and treatment decisions, as illustrated by an index patient.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Douglas I. Lin, Yakov Chudnovsky, Bridget Duggan, Deborah Zajchowski, Joel Greenbowe, Jeffrey S. Ross, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin,